Panbela Therapeutics (NASDAQ:PBLA) Rating Reiterated by HC Wainwright

HC Wainwright restated their neutral rating on shares of Panbela Therapeutics (NASDAQ:PBLA) in a research note released on Thursday morning, Benzinga reports. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($1.63) EPS, Q4 2024 earnings at ($1.61) EPS, FY2024 earnings at ($6.76) EPS, FY2025 earnings at ($4.44) EPS, FY2026 earnings at ($3.43) EPS, FY2027 earnings at ($1.55) EPS and FY2028 earnings at $0.01 EPS.

Panbela Therapeutics Price Performance

Shares of NASDAQ PBLA opened at $0.37 on Thursday. Panbela Therapeutics has a 1-year low of $0.30 and a 1-year high of $38.00. The firm has a market capitalization of $1.28 million, a PE ratio of 0.00 and a beta of 1.58. The business’s fifty day moving average price is $0.37 and its two-hundred day moving average price is $0.58.

Panbela Therapeutics Company Profile

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.